MedTrace Logo

Efficacy of the Erector Spinae Plane Block for Persistent Back Pain in Patients With Ankylosing Spondylitis

NCT07633730 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-06-08

No results posted yet for this study

Summary

Despite adequate control of disease activity with standard medical therapies, there remains an ongoing need for complementary and interventional approaches for the management of persistent back pain in patients with ankylosing spondylitis. Although the erector spinae plane block has been described in the literature as a safe and effective analgesic intervention for chronic back pain in various patient populations, to the best of our knowledge, no clinical study has specifically evaluated its use for persistent back pain in patients with ankylosing spondylitis receiving medical treatment. Therefore, the present study aims to evaluate the effects of erector spinae plane block on pain severity and clinical outcomes in patients with ankylosing spondylitis whose disease activity is controlled under treatment but who continue to experience persistent back pain.

Conditions

  • Ankylosing Spondylitis (AS)
  • Back Pain
  • ESPB
  • Regional Anesthesia

Interventions

PROCEDURE

Erector spinae plane block(ESBP)

The procedure will be performed in the prone position under sterile conditions and ultrasound guidance. Using a 22-gauge needle at the T5-T7 vertebral levels, the fascial plane between the deep fascia of the erector spinae muscle group and the transverse process of the vertebra will be accessed. A combination consisting of 5 cc of 0.5% bupivacaine, 4 cc of 0.9% normal saline, and 1 cc dexamethasone (8 mg/2 mL) will then be injected into the targeted plane. The procedure will be performed by experienced algology specialists with more than 15 years of experience in ultrasound-guided interventional procedures and will be administered in two sessions within one week.

Sponsors & Collaborators

  • Marmara University

    lead OTHER

Principal Investigators

  • Fatma B Akdağ, Research Assistant · Marmara University Faculty of Medicine ,Marmara University, Department of Physical Medicine and Rehabilitation

  • Savaş Şencan, Associate Professor · Algology Division, Department of Physical Medicine and Rehabilitation, Marmara University Faculty of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-02
Primary Completion
2027-05-02
Completion
2027-06-02

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07633730 on ClinicalTrials.gov